US$ 23.06
ipamorelin clinical trial safety adverse effects trials What happens if an adult patient with no underlying severe ipamorelin adverse effects clinical trial
Description
Briken V, Miller JL
Summary Ipamorelin is a synthetic pentapeptide and selective ghrelin-receptor (GHS-R1a) agonist, developed through targeted modification of earlier GHRP compounds to improve enzymatic stability and receptor selectivity

time of predicted and observed data

N Engl J Med 358, 14831494 (2008)

AUC 0-last , AUC 0-final time point
